HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price Target
HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ: BCRX ) with a Buy and maintains $32 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.